Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
At what age do you stop LDCT chest for lung cancer screening?
One of Medicine's three priority-ordered duties is to postpone death. This also pertains to persons who have reached age 81. Lung cancer can occur longer than 15 years after cessation of smoking. Even if surgery can't be done, primary radiation of Stage 1 squamous cell lung carcinoma can result in p...
How would you approach a patient with metastatic ER/PR+, HER2- breast cancer with linear leptomeningeal enhancement on MRI but negative CSF protein and cytology?
First, it is important to note that the sensitivity of CSF cytology depends on both the number of LPs and the volume of LP. For example, one LP has a sensitivity of only ~70%, while doing more than 3 LPs takes the sensitivity up to 98%. Similarly, withdrawing at least 10 ml of CSF improves sensitivi...
How, if at all, does your systemic therapy management differ between HER2+ breast cancer patients with active CNS metastases compared to those with stable/treated CNS metastases?
For HER2+ breast cancer patients with active CNS metastases, the focus is on using systemic therapies with proven CNS penetration, such as tucatinib combined with trastuzumab and capecitabine or T-DXd, to address both systemic and CNS disease. In contrast, for those with stable or treated CNS metast...
What experience have you had with familial clustering of polycythemia vera?
JAK2 V617F is a somatic mutation that can be acquired as early as in utero based on elegant work by Williams et al., PMID 35058638.There is some data available regarding familial MPN predisposition syndromes and this review very nicely summarizes much of the available data (Lim et al., PMID 39316992...
Do you have a preferred IV iron formulation for pregnant women?
I prefer INFeD, Feraheme, Monoferric, and FCM is okay. INFeD, Feraheme, and Monoferric are also preferred in non-pregnant patients. FCM in non-pregnant patients has a risk of hypophosphatemia, but for some reason, FCM (InjectaFer) does not cause hypophosphatemia in pregnancy, likely due to renal ada...
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
Thanks for the important question. This is a nice but also challenging situation given, at this time, we do not have evidence for organ preservation with chemotherapy alone. Nonetheless, the PROSPECT trial did show approximately 20% of patients indeed achieved pathological compete response (was quit...
Is there a rationale for treating medically inoperable stage I-III breast cancer patients with RT alone?
We treated stage III patients with "radical radiotherapy" with or without chemotherapy when I was a resident in the early 1980s, since they were considered SURGICALLY inoperable then. However, very high doses were needed (75-80 Gy to the primary using external beam followed by interstitial implants)...
How do you dose apixaban in patients with CrCl <30 mL/minute?
Patients with chronic kidney disease are challenging to treat with anticoagulation as they have an increased risk of both venous thromboembolism and bleeding. Treatment should be individualized after weighing the risks and benefits of anticoagulation as well as the indication for anticoagulation. Th...
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
In the ADRIATIC study, stage I or II limited-stage SCLC comprised only about 12% of patients randomized. The point estimate of HR regarding survival benefit was 0.92, with a wide confidence interval exceeding 1.0 (upper range more than 2). I do not recommend durvalumab consolidation for those with s...
How do you manage a patient with JAK2+ ET without history of thrombosis during pregnancy?
Great question. We've recently published our experience here How et al., PMID 33022566. Patients with ET that are pregnant and that don't have a history of thrombosis are likely to be in the very low/low risk categories by R-IPSET, many of these women are likely not on any treatment prior to startin...